Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal
Recent progress in the development of molecular cancer therapeutics has revealed new
types of antitumor drugs, such as Herceptin, Gleevec, and Iressa, as potent therapeutics for …
types of antitumor drugs, such as Herceptin, Gleevec, and Iressa, as potent therapeutics for …
Novel brain function: biosynthesis and actions of neurosteroids in neurons
K Tsutsui, K Ukena, M Usui, H Sakamoto… - Neuroscience …, 2000 - Elsevier
Peripheral steroid hormones act on brain tissues through intracellular receptor-mediated
mechanisms to regulate several important brain neuronal functions. Therefore, the brain is …
mechanisms to regulate several important brain neuronal functions. Therefore, the brain is …
[PDF][PDF] CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant
H Sakamoto, T Tsukaguchi, S Hiroshima, T Kodama… - Cancer cell, 2011 - cell.com
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain
cancers, following gene alterations such as chromosomal translocation, amplification, or …
cancers, following gene alterations such as chromosomal translocation, amplification, or …
[HTML][HTML] A new protein containing an SH2 domain that inhibits JAK kinases
…, M Masuhara, M Yokouchi, R Suzuki, H Sakamoto… - Nature, 1997 - nature.com
… 78–180 of human JAB) in kinase buffer (50 mM HEPES, pH 7.5, 50 mM NaCl, 5 mM MgCl
2 , 5 mM MnCl 2 and 0.1 mM Na 3 VO 4 ) in thepresence or absence of 0.2 mM ATP for 2 h at …
2 , 5 mM MnCl 2 and 0.1 mM Na 3 VO 4 ) in thepresence or absence of 0.2 mM ATP for 2 h at …
Advantages of using both voxel-and surface-based morphometry in cortical morphology analysis: a review of various applications
…, S Konishi, Y Masutani, H Sakamoto… - Magnetic resonance in …, 2022 - jstage.jst.go.jp
In addition, we introduce two other recent methods as future directions for estimating cortical
morphological changes: a multi-modal parcellation method using structural and functional …
morphological changes: a multi-modal parcellation method using structural and functional …
Highly controlled acetylene accommodation in a metal–organic microporous material
…, Y Kubota, RV Belosludov, TC Kobayashi, H Sakamoto… - Nature, 2005 - nature.com
… To elucidate the mechanism of high adsorption ability for C 2 H 2 molecules in complex 1,
we determined the structure of complex 1 with adsorbed C 2 H 2 molecules by the MEM (…
we determined the structure of complex 1 with adsorbed C 2 H 2 molecules by the MEM (…
KIF5B-RET fusions in lung adenocarcinoma
…, K Yasuda, M Hiramoto, T Nammo, H Sakamoto… - Nature medicine, 2012 - nature.com
We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET
oncogene, which are present in 1–2% of lung adenocarcinomas (LADCs) from people from …
oncogene, which are present in 1–2% of lung adenocarcinomas (LADCs) from people from …
[HTML][HTML] The JAK‐binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop
H Yasukawa, H Misawa, H Sakamoto… - The EMBO …, 1999 - embopress.org
The Janus family of protein tyrosine kinases (JAKs) regulate cellular processes involved in
cell growth, differentiation and transformation through their association with cytokine receptors…
cell growth, differentiation and transformation through their association with cytokine receptors…
[PDF][PDF] Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
T Takano, Y Ohe, H Sakamoto, K Tsuta… - J Clin …, 2005 - mhlw-grants.niph.go.jp
… HART consisted of a total dose of 576 Gy in 36 fractions delivered over 15 days using
three-times daily fractions with a 4-h interval between fractions and an 8-h interval between on-…
three-times daily fractions with a 4-h interval between fractions and an 8-h interval between on-…
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
…, Y Kaneoka, Y Shimizu, S Nakamori, H Sakamoto… - The Lancet, 2016 - thelancet.com
Background Although adjuvant chemotherapy with gemcitabine is standard care for resected
pancreatic cancer, S-1 has shown non-inferiority to gemcitabine for advanced disease. We …
pancreatic cancer, S-1 has shown non-inferiority to gemcitabine for advanced disease. We …